The THP-1 M0-MΦ were incubated for 24 h with LPS (10 pg/ml, Sigma-Aldrich Co. LLC, St.Louis, USA) and IFN-γ (20 ng/ml, Provitro GmbH, Berlin) to differentiate into pro-inflammatory M1-MΦ [THP-1 M1-MФ]. For differentiation into anti-inflammatory M2-MΦ IL-4 (20 ng/ml, Provitro GmbH) and IL-13 (20 ng/ml, Provitro GmbH) were used for 24 h [THP-1 M2-MФ]. To control the successful differentiation of THP-1 into M1-/M2-MΦ, CCR7 and CCL17 mRNA expressions, as well as TNF-α, and IL-10 releases, were analyzed (6 (link)–8 (link), 36 (link), 37 (link)) (Additional File Figure S1 ). To examine the effect of PACAP38 (Bachem AG, Bubendorf, Schweiz), VPAC1-agonist [Ala11,22,28]VIP (Cat. Nr. 4040136, Bachem AG) or -antagonist [PG 97–269] (Cat. Nr. 4048647, Bachem AG), the THP-1 MФ were incubated for 24 h with PACAP38 (0.1 nM), [Ala11,22,28]VIP (0.1 nM) or PG 97–269 (10 nM) with or without 50 µg/ml oxLDL. PACAP38 concentration has been specified by Rasbach et al. (29 (link)).
Pg 97 269
Manufactured by Bachem
Sourced in United States
PG 97–269 is a laboratory equipment product manufactured by Bachem. It is designed for use in research and development applications. The core function of this product is to provide a tool for performing specific tasks or experiments in a controlled laboratory environment.
Automatically generated - may contain errors
Lab products found in correlation
Bicuculline methochloride, by Bio-Techne (1 mentions)
Charybdotoxin, by Merck Group (1 mentions)
Wortmannin, by Cayman Chemical (1 mentions)
6 cyano 7 nitroquinoxaline 2 3 dione cnqx, by Bio-Techne (1 mentions)
Apamin, by Merck Group (1 mentions)
D 2 amino 5 phosphonopentanoic acid, by Bio-Techne (1 mentions)
Ucl2077, by Bio-Techne (1 mentions)
Tram 34, by MedChemExpress (1 mentions)
Pg99 465, by Bachem (1 mentions)
Lipopolysaccharides (lps), by Merck Group (1 mentions)
2 protocols using pg 97 269
1
Differentiating THP-1 Cells into M1 and M2 Macrophages
2
Pharmacological Modulation of Neuronal Signaling
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Drugs were kept in 500X-1,000X stock solutions and diluted in SFM prior the experiments. (-)-Bicuculline methochloride (BIC; GABAA receptor antagonist), d(-)-2-amino-5-phosphonopentanoic acid (d-AP5; NMDA receptor antagonist), 6-Cyano-7-nitroquinoxaline-2,3-dione (CNQX; AMPA/kainate receptor antagonist) and bisindolylmaleimide X (BIM-X; protein kinase C blocker) were purchased from Tocris (Bristol, UK) or Cayman Chemical (Ann Arbor, MI). SQ 25236 (adenylyl cyclase blocker) and UCL2077 (slow afterhyperpolarization blocker) were obtained from Tocris. TRAM-34 (KCa3.1 blocker) was obtained by MedChemExpress (Monmouth Juntion, NJ, USA). Rp-cAMPS triethylammonium salt (protein kinase A blocker), charybdotoxin (ChTx; fast afterhyperpolarization blocker) and apamin (medium afterhyperpolarization blocker) were obtained from Sigma (Saint-Louis, MO, USA). PG97-269 and PG99-465 (VPAC1 and VPAC2 blockers, respectively) were obtained from Bachem (Torrance, CA, USA). Cholera toxin (CTX) and wortmannin were obtained from Cayman Chemical. Vasoactive intestinal peptide (VIP) was obtained from Phoenix Pharmaceuticals (Burlingame, CA, USA).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!